ES2084940T3 - Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas. - Google Patents

Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas.

Info

Publication number
ES2084940T3
ES2084940T3 ES92305287T ES92305287T ES2084940T3 ES 2084940 T3 ES2084940 T3 ES 2084940T3 ES 92305287 T ES92305287 T ES 92305287T ES 92305287 T ES92305287 T ES 92305287T ES 2084940 T3 ES2084940 T3 ES 2084940T3
Authority
ES
Spain
Prior art keywords
lymphoma
rapamicine
treatment
adult leukemia
atl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92305287T
Other languages
English (en)
Inventor
Glenn Alvin Miller
Mark Barry Rabin
William Joseph Jnr Harrington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2084940T3 publication Critical patent/ES2084940T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

ESTE INVENTO PROPORCIONA UN METODO PARA TRATAR CELULAS T ADULTAS DE LEUCEMIA/LINFOMA (ATL) EN UN MAMIFERO QUE LO NECESITE QUE COMPRENDE LA ADMINISTACION DE UNA CANTIDAD ANTIPROLIFERATIVA DE RAPAMICIN Y ES PARTICULARMENTE UTIL EN ATAJAR O HACER REMITIR ATL.
ES92305287T 1991-06-18 1992-06-09 Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas. Expired - Lifetime ES2084940T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71777391A 1991-06-18 1991-06-18

Publications (1)

Publication Number Publication Date
ES2084940T3 true ES2084940T3 (es) 1996-05-16

Family

ID=24883429

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92305287T Expired - Lifetime ES2084940T3 (es) 1991-06-18 1992-06-09 Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas.

Country Status (20)

Country Link
EP (1) EP0525960B1 (es)
JP (1) JP2562548B2 (es)
KR (1) KR930000115A (es)
AT (1) ATE135583T1 (es)
AU (1) AU651698B2 (es)
CA (1) CA2071456A1 (es)
CZ (1) CZ281663B6 (es)
DE (1) DE69209183T2 (es)
DK (1) DK0525960T3 (es)
ES (1) ES2084940T3 (es)
GR (1) GR3019749T3 (es)
HK (1) HK108897A (es)
HU (1) HU214326B (es)
IE (1) IE71646B1 (es)
IL (1) IL102185A (es)
MX (1) MX9202939A (es)
NZ (1) NZ243175A (es)
SG (1) SG43072A1 (es)
SK (1) SK279804B6 (es)
ZA (1) ZA924369B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
JPH08509499A (ja) 1993-04-23 1996-10-08 アボツト・ラボラトリーズ ラパマイシン結合体及び抗体
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
AU4919597A (en) * 1996-10-31 1998-05-22 American Home Products Corporation Synergistic composition comprising rapamycin and calcitriol
CN1245423A (zh) 1996-12-30 2000-02-23 巴特勒纪念研究院 采用吸入法治疗肿瘤的制剂和方法
CA2230748C (en) * 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
RU2184541C2 (ru) * 1997-06-13 2002-07-10 Американ Хоум Продактс Корпорейшн Препараты рапамицина для орального применения
CN1296413A (zh) * 1998-02-04 2001-05-23 应用遗传学及皮肤学公司 调节应答于基因毒物的细胞因子释放的组合物和方法
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
DE60142677D1 (de) 2000-01-14 2010-09-09 Univ Pennsylvania O-methylierte rapamycinderivate zur milderung oder vermeidung lymphoproliferativer erkrankungen
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
JP2004509898A (ja) 2000-09-19 2004-04-02 ワイス 水溶性ラパマイシンエステル
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
PL367267A1 (en) * 2001-06-01 2005-02-21 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US6680330B2 (en) 2001-08-22 2004-01-20 Wyeth Rapamycin dialdehydes
ES2246409T3 (es) 2001-08-22 2006-02-16 Wyeth 29-enoles de rapamicina.
AU2003247483A1 (en) * 2002-05-30 2003-12-31 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
PT1553940E (pt) 2002-07-30 2008-05-09 Wyeth Corp Formulações parentéricas contendo um hidroxi-éster de rapamicina
AR042938A1 (es) 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
CN1942478A (zh) 2004-04-14 2007-04-04 惠氏公司 用于制备与二羧酸的纳巴霉素42-酯和fk-506 32-酯的方法,用于纳巴霉素配合物的前体和抗体
ME02695B (me) 2004-05-13 2017-10-20 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3- delta kinaze
CA2567883A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
CN101360495B (zh) 2005-11-14 2012-03-14 阿里亚德医药股份有限公司 对癌症病人给药mTOR抑制剂
US7867988B2 (en) 2006-09-13 2011-01-11 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
JP5794919B2 (ja) 2008-11-13 2015-10-14 ギリアード カリストガ エルエルシー 血液学的な悪性疾患のための療法
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102439012A (zh) 2009-03-24 2012-05-02 吉里德卡利斯托加公司 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
EP2416792A4 (en) 2009-04-10 2012-10-24 Haiyan Qi NEW ANTI-AGING APPROACHES AND METHOD FOR IDENTIFYING THEM
EP2421536B1 (en) 2009-04-20 2015-08-26 Gilead Calistoga LLC Methods of treatment for solid tumors
AU2010276160A1 (en) 2009-07-21 2012-02-09 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
AU2012351728A1 (en) 2011-12-16 2014-06-19 Oncology Institute Of Southern Switzerland Combination of inotuzumab ozogamicin and torisel for the treatment of cancer
EA201691327A1 (ru) 2012-03-05 2017-03-31 Джилид Калистога Ллс Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
CA2934534A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
CN105849108A (zh) 2013-12-20 2016-08-10 吉利德卡利斯托加公司 磷脂酰肌醇3-激酶抑制剂的制备方法
MA40059A (fr) 2014-06-13 2015-12-17 Gilead Sciences Inc Inhibiteurs de la phosphatidylinositol 3-kinase
SG11201908226XA (en) 2017-02-10 2019-10-30 Mount Tam Therapeutics Inc Rapamycin analog

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
GB8610114D0 (en) * 1986-04-25 1986-05-29 Esselte Letraset Ltd Sign-making materials

Also Published As

Publication number Publication date
HU9202023D0 (en) 1992-09-28
CZ281663B6 (cs) 1996-12-11
SK279804B6 (sk) 1999-04-13
IE71646B1 (en) 1997-02-26
DE69209183D1 (de) 1996-04-25
SG43072A1 (en) 1997-10-17
KR930000115A (ko) 1993-01-15
MX9202939A (es) 1994-05-31
IE921957A1 (en) 1992-12-30
HU214326B (hu) 1998-03-02
JP2562548B2 (ja) 1996-12-11
GR3019749T3 (en) 1996-07-31
NZ243175A (en) 1997-06-24
EP0525960A1 (en) 1993-02-03
AU1825592A (en) 1992-12-24
IL102185A (en) 1997-09-30
DK0525960T3 (da) 1996-04-15
CZ182492A3 (en) 1993-12-15
DE69209183T2 (de) 1996-08-08
EP0525960B1 (en) 1996-03-20
ATE135583T1 (de) 1996-04-15
JPH05170771A (ja) 1993-07-09
ZA924369B (en) 1993-12-15
HUT61480A (en) 1993-01-28
SK182492A3 (en) 1994-10-05
AU651698B2 (en) 1994-07-28
CA2071456A1 (en) 1992-12-19
HK108897A (en) 1997-08-22

Similar Documents

Publication Publication Date Title
ES2084940T3 (es) Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas.
LV11116A (lv) Virsmas notirisana ar apstarojuma palidzibu
DK0414289T3 (da) Spirocykliske, antipsykotiske midler
ATE141812T1 (de) Fallschutzgerat
DE69308109D1 (de) Sicherheitsgurtführung
DE68908231D1 (de) Roentgenuntersuchungsapparat mit einstellbarer schlitzfoermiger blende.
DE68904029D1 (de) Sicherheitsgurtvorrichtung.
ES2089723T3 (es) 29-demetoxirapamicina para inducir la inmunodepresion.
DE68904971D1 (de) Vorrichtung zum stapeln von flachen gegenstaenden, wie briefe.
FI870506A (fi) Saollningsanlaeggning med sammanbyggd foerdelnings- och avskiljningsanordning.
DK0458589T3 (da) Behandling af okulær hypertension med en okulær synergistisk kombination
DE69014221D1 (de) Bandführungsvorrichtung.
PT656209E (pt) Derivados de melatonina para uso no tratamento de perturbacoes de dessincronizacao
FI940519A0 (fi) Interleukiini-10-analogien tai -antagonistien käyttö endotoksiinin taisuperantigeenin indusoiman toksisuuden hoitamiseksi
ATE285789T1 (de) Mukosale zytotoxische t-lymphozytenantwort
FI903742A0 (fi) Foerfarande foer diskontinuerlig framstaellning av l-carnitin pao mikrobiologisk vaeg.
DE59200188D1 (de) Gurtaufroller mit Komforteinrichtung.
DE58900132D1 (de) Verfahren und vorrichtung zum montieren von riemen an riementrieben.
ATE83907T1 (de) Vorrichtung zum offenhalten eines ureterotomieschnitts.
DE69013938D1 (de) Sicherheitsgurtvorrichtung.
DE69208404D1 (de) Vorrichtung zur Unterdrückung von Riemengeräuschen und -schwingungen
ES1013657Y (es) Aparato de gimnasia por poleas.
SE9200281D0 (sv) Anordning foer rullstol med bilbaelte
ATE178733T1 (de) Vorrichtung zur informationsvermittlung
ES271525Y (es) Dispositivo de regulacion de la inclinacion relativa de dos organos y especialmente de la base y del respaldo de un asiento de automovil.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 525960

Country of ref document: ES